retatrutide type 2 diabetes trial results 2024 2025 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished I personally know plenty of

Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity

Weight loss medications are no different, especially when the potential health benefits are so large

This influences the neuroendocrine regulation of hunger and satiety, leading to reduced food intake without conscious effort to limit calories

Presented for research literature review only Butuca A et al

Verify volume, expel any air bubbles 6

CJC-1295 No DAC vs Ipamorelin:GHRH Analogue vs GH Secretagogue Research CJC-1295 No DAC and Ipamorelin are commonly paired in GH-axis and body-composition research discussions, but they interact with different points of the growth-hormone signalling model